Abstract YO20
Case summary
This is the case of an 62-year-old man who had symptoms such as splenomegaly +10 cm below the costal arch, very high WBC (169*10/9/L), immature granulocytes in CBC ( 7%), low PLT count (85*10/9/L), low HGB level (11.2 g/dL) and monocytosis (22% or 37*10/9/L). He was admitted to hematology clinic in our center. He also presented with hypercellularity with high count of monocytes in bone marrow (18%) and the blasts count was 7%. We did cytogenetic test of bone marrow by standard method. The karyotype was 48, XYY, +13 [20]. In additional we did cytogenetic analysis of lymphocytes stimulated by phytohaemagglutinin. The final cytogenetic conclusion showed that the patient had XYY syndrome or “superman” syndrome. This is rare congenital genetic disorder which often becomes unrecognized. The patient received final hematological diagnosis of Chronic Myelomonocytic Leukemia-1 by WHO 2017 classification. Therapy was invited with Hydroxyurea during 6 months without remission and with progression to acute myeloid leukemia. The second line was chemotherapy of 6-mercaptopurinum and low doses of cytarabine. In spite of treatment, the patient ultimately died from progression AML. It is known, that patients with some different congenital genetic disorders, such as Dawn`s syndrome, Fanconi anemia, severe congenital neutropenia, Shwachman-Diamond syndrome and others, have high risk of leukemia. However, there are very little clinical cases described in science press. It was one of these rare cases. So, can “superman” have a CMML? Yes, if he has acquired trisomy 13.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
4P - Impact of chemotherapy and radiotherapy on tissue expander or implant removal in breast cancer patients
Presenter: Sungmi Jung
Session: Poster display session
Resources:
Abstract
5P - Long-term prognostic effect of hormone receptor subtype on breast cancer
Presenter: Ki-tae Hwang
Session: Poster display session
Resources:
Abstract
6P - Effect of apparent diffusion coefficient in predicting pathologic responses in patients with breast cancer treated with neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel
Presenter: Yutaka Mizuno
Session: Poster display session
Resources:
Abstract
7P - Current diagnostic strategy for mammographic microcalcification without specific ultrasound abnormality
Presenter: Naoki Sato
Session: Poster display session
Resources:
Abstract
8P - Comparison of standard uptake value of 18F-FDG-PET-CT with tumour-infiltrating lymphocytes in breast cancer ≥1cm
Presenter: Soeun Park
Session: Poster display session
Resources:
Abstract
10P - Prognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer
Presenter: Seungtaek Lim
Session: Poster display session
Resources:
Abstract
11P - The prognosis of rare histopathologic subtype of breast cancer
Presenter: Soo Youn Bae
Session: Poster display session
Resources:
Abstract
12P - Daily collection of physical activity via smartphone application and smart band for development of distress screening tools in breast cancer survivors: A feasibility study
Presenter: Yungil Shin
Session: Poster display session
Resources:
Abstract
13P - Breast cancer distribution in East Azerbaijan, Iran: Results of population-based cancer registry
Presenter: Shima Pashaei
Session: Poster display session
Resources:
Abstract
14P - Validation of the optimum timing of assessment of tumour infiltrating lymphocytes during preoperative chemotherapy for breast cancer
Presenter: Shinichiro Kashiwagi
Session: Poster display session
Resources:
Abstract